From multi-target mechanisms to clinical translation: the analgesic potential of quercetin
Abstract
As a major global health challenge, pain often eludes optimal management by current therapies due to limitations like side effects and inadequate efficacy in certain subtypes. Quercetin, a natural flavonoid, has emerged as a promising broad-spectrum analgesic, demonstrating efficacy in diverse pain models including inflammatory, neuropathic, and cancer-related pain. This review systematically delineates the broad-spectrum analgesic efficacy of quercetin across diverse pain conditions, including inflammatory, neuropathic, cancer, and postoperative pain. We comprehensively dissect its sophisticated molecular mechanisms, encompassing the suppression of neuroinflammation via modulating glial cell activation and polarization, the mitigation of oxidative stress and ferroptosis, the regulation of key ion channels and neuroreceptors, and the restoration of neural pathway homeostasis. Furthermore, we discuss innovative drug delivery strategies designed to overcome quercetin's pharmacokinetic limitations and enhance its therapeutic potential. Despite promising preclinical results, challenges in clinical translation, particularly regarding bioavailability and the need for robust clinical validation, are critically examined. By integrating the latest preclinical and clinical evidence and providing a pain-centric, mechanism-driven analytical framework, this review addresses the critical gap in dedicated research on quercetin's analgesic properties and offers a novel theoretical basis for…
Read the paper
Related studies
- Meta-analysis of genome-wide association for migraine in six population-based European cohorts
- New and sex-specific migraine susceptibility loci identified from a multiethnic genome-wide meta-analysis
- microRNA profiling in atherosclerosis, diabetes, and migraine
- Genome‐Wide‐Associated Variants in Migraine Susceptibility: A Replication Study From North I ndia
- Pharmacoinformatics elucidation of potential drug targets against migraine to target ion channel protein KCNK18
- Upregulation of IL-1 Receptor Antagonist in a Mouse Model of Migraine
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.